Fitting models to the COVID-19 outbreak and estimating R.

Matt J. Keeling[1*], Louise Dyson[1‡], Glen Guyver-Fletcher[1,3], Alex Holmes[1,2], Malcolm G Semple[5,6], ISARIC4C Investigators, Michael J. Tildesley[1‡], Edward M. Hill[1‡].

1 The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, United Kingdom.
2 Mathematics for Real World Systems Centre for Doctoral Training, Mathematics Institute, University of Warwick, Coventry, CV4 7AL, United Kingdom.
3 Midlands Integrative Biosciences Training Partnership, School of Life Sciences, University of Warwick, Coventry, CV4 7AL, United Kingdom.
4 Department of Statistics, University of Warwick, Coventry, CV4 7AL, United Kingdom.
5 NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom.
6 Respiratory Medicine, Alder Hey Children's Hospital, Institute in The Park, University of Liverpool, Alder Hey Children's Hospital, Liverpool L12 2AP, United Kingdom.

‡These authors contributed equally to this work.

* Corresponding Author. Email: M.J.Keeling@warwick.ac.uk

Abstract

The COVID-19 pandemic has brought to the fore the need for policy makers to receive timely and ongoing scientific guidance in response to this recently emerged human infectious disease. Fitting mathematical models of infectious disease transmission to the available epidemiological data provides a key statistical tool for understanding the many quantities of interest that are not explicit in the underlying epidemiological data streams. Of these, the basic reproductive ratio, R, has taken on special significance in terms of the general understanding of whether the epidemic is under control ($R < 1$). Unfortunately, none of the epidemiological data streams are designed for modelling, hence assimilating information from multiple (often changing) sources of data is a major challenge that is particularly stark in novel disease outbreaks.

Here, we present in some detail the inference scheme employed for calibrating the Warwick COVID-19 model to the available public health data streams, which span hospitalisations, critical care occupancy, mortality and serological testing. We then perform computational simulations, making use of the acquired parameter posterior distributions, to assess how the accuracy of short-term predictions varied over the timecourse of the outbreak. To conclude, we compare how refinements to data streams and model structure impact estimates of epidemiological measures, including the estimated growth rate and daily incidence.

1 Introduction

In late 2019, accounts emerged from Wuhan city in China of a virus of unknown origin that was leading to a cluster of pneumonia cases [1]. The virus was identified as a novel strain of coronavirus on 7th January 2020 [2], subsequently named Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), causing the respiratory syndrome known as COVID-19. The outbreak has since developed into a global pandemic. As of 3rd August 2020 the number of confirmed COVID-19 cases is approaching 18 million, with more than 685,000 deaths occurring worldwide [3]. Faced with these threats, there is a need for robust predictive models that can help policy makers by quantifying the impact of a range of potential responses. However, as is often stated, models are only as good as the data that underpins them; it is therefore important to examine, in some detail, the parameter inference methods and agreement between model predictions and data.

In the UK, the first cases of COVID-19 were reported on 31st January 2020 in the city of York. Cases continued to be reported sporadically throughout February and by the end of the month guidance was issued stating that travellers from the high-risk epidemic hotspots of Hubei province in China, Iran and South Korea should self-isolate upon arrival in the UK. By mid-March, as the number of cases began to rise, there was advice against all non-essential travel and, over the coming days, several social-distancing measures were introduced including the closing of schools, non-essential shops, pubs and restaurants. This culminated in the introduction of a UK lockdown, announced on the evening of 23rd March, whereby the public were instructed to remain at home with four exceptions: shopping for essentials; any medical emergency; for one form of exercise per day; and to travel to work if absolutely necessary. By mid-April, these stringent mitigation strategies began to have an effect, as the number of confirmed cases and deaths as a result of the disease began to decline. As the number of daily confirmed cases continued to decline during April, May and into June, measures to ease lockdown restrictions began, with the re-opening of some non-essential businesses and allowing small groups of individuals from different households to meet up outdoors, whilst maintaining social distancing. This was followed by gradually re-opening primary schools in England from 1st June and all non-essential retail outlets from 15th June. Predictive models for the UK are therefore faced with a changing set of behaviours against which historic data must be judged, and an uncertain future of potential additional relaxations.

Throughout, a significant factor in the decision-making process was the value of the effective reproduction number, R of the epidemic; this quantity was estimated by several modelling groups that provided advice through the Scientific Pandemic Influenza Modelling Group (SPI-M) [4]. The Warwick COVID-19 model presented here provided one source of R estimates through SPI-M. When R is estimated to be significantly below one, such that the epidemic is exponentially declining, then there is scope for some relaxation of intervention measures. However, as R_t approaches one, further relaxation of control may lead to cases starting to rise again. It is therefore crucial that models continue to be fitted to the latest epidemiological data in order for them to provide the most robust information regarding the impact of any relaxation policy and the effect upon the value of R_t. It is important to note, however, that there will necessarily be a delay between any change in behaviour, the epidemiological impact and the ability of an statistical method to detect this change.

The initial understanding of key epidemiological characteristics for a newly emergent infectious disease is, by its very nature of being novel, extremely limited and often biased towards early severe cases. Developing models of infectious disease dynamics enables us to challenge and improve our mechanistic understanding of the underlying epidemiological processes based on a variety of data sources. One way such insights can be garnered is through model fitting / parameter inference, the process of estimating the parameters of the mathematical model from data. The task of fitting a model to data is often challenging, partly due to the necessary complexity of the model in use, but also because of data

limitations and the need to assimilate information from multiple sources of data [5].

Throughout this work, the process of model fitting is performed under a Bayesian paradigm, where model parameters are assumed to be random variables and have joint probability distributions [6]. These probability distributions quantify uncertainty in the model parameters, which can be translated into uncertainty in model predictions. We take a likelihood-based approach, in which we define the likelihood (the probability of observing the data given a particular model and parameter set) and use the likelihood to find the probability distribution of our model parameters. In particular, we use Markov Chain Monte Carlo (MCMC) schemes to find the posterior probability distribution of our parameter set given the data and our prior beliefs. MCMC methods construct a Markov chain which converges to the desired posterior parameter distribution at steady state [7]. Simulating this Markov chain thus allows us to draw sets of parameters from the joint posterior distribution.

As stated above, the parameter uncertainty may then be propagated if using the model to make projections. This affords models with mechanistic aspects, through computational simulation, the capability of providing an estimated range of predicted possibilities given the evidence presently available. Thus, models can demonstrate important principles about outbreaks [8], with examples during the present pandemic including analyses of the effect of non-pharmaceutical interventions on curbing the outbreak of COVID-19 in the UK [9].

In this paper, we present the inference scheme, and its subsequent refinements, employed for calibrating the Warwick COVID-19 model [10] to the available public health data streams and estimating key epidemiological quantities such as R.

We begin by describing our mechanistic transmission model for SARS-CoV-2 in section 2, detailing in section 3 how the effects of social distancing are incorporated within the model framework. In order to fit the model to data streams pertaining to critical care, such as hospital admissions and bed occupancy, section 4 expresses how epidemiological outcomes were mapped onto these quantities. In section 5, we outline how these components are incorporated into the likelihood function and the adopted MCMC scheme. The estimated parameters are then used to measure epidemiological measures of interest, such as the growth rate (r), with the approach detailed in section 6.

The closing sections draw attention to how model frameworks may evolve during the course of a disease outbreak as more data streams become available and we collectively gain a better understanding of the epidemiology (section 7). We explore how key epidemiological quantities, in particular the reproduction number R and the growth rate r, depend on the data sources used to underpin the dynamics. To finish, we outline the latest fits and model generated estimates using data up to mid-June (section 9).

2 Model description

We present here the system of equations that account for the transmission dynamics, including symptomatic and asymptomatic transmission, household saturation of transmission and household quarantining. The population is stratified into multiple compartments: individuals may be susceptible (S), exposed (E), with detectable infection (symptomatic D), or undetectable infection (asymptomatic, U). Undetectable infections are assumed to transmit infection at a reduced rate given by τ. We let superscripts denote the first infection in a household (F), a subsequent infection from a detectable/symptomatic household member (SD) and a subsequent infection from an asymptomatic household member (SU). A fraction (H) of the first detected case in a household is quarantined (QF), as are all their subsequent household infections (QS) - we ignore the impact of household quarantining on the susceptible population as the number in quarantine is assumed small compared with the rest of the population. The recovered class is not explicitly modelled, although it may become important once we have a better understanding of the duration of immunity. Natural demography and disease-induced mortality are ignored in the formulation of the epidemiological dynamics.

Model equations

The full equations are given by

$$
\begin{aligned}
\frac{dS_a}{dt} &= -\left(\lambda_a^F + \lambda_a^{SD} + \lambda_a^{SU} + \lambda_a^Q\right)\frac{S_a}{N_a}, \\
\frac{dE_{1,a}^F}{dt} &= \lambda_a^F \frac{S_a}{N_a} - M\varepsilon E_{1,a}^F, \\
\frac{dE_{1,a}^{SD}}{dt} &= \lambda^{SD} \frac{S_a}{N_a} - M\varepsilon E_{1,a}^{SD}, \\
\frac{dE_{1,a}^{SU}}{dt} &= \lambda^{SU} \frac{S_a}{N_a} - M\varepsilon E_{1,a}^{SU}, \\
\frac{dE_{1,a}^{Q}}{dt} &= \lambda^{Q} S - M\varepsilon E_{1,a}^{Q}, \\
\frac{dE_{m,a}^{X}}{dt} &= M\varepsilon E_{m-1,a}^{X} - M\varepsilon E_{m,a} \qquad X \in \{F, SD, SU, Q\} \\
\frac{dD_a^F}{dt} &= d_a(1-H)M\varepsilon E_{M,a}^F - \gamma D_a^F, \\
\frac{dD_a^{SD}}{dt} &= d_a M\varepsilon E_{M,a}^{SD} - \gamma D_a^{SD}, \\
\frac{dD_a^{SU}}{dt} &= d_a(1-H)M\varepsilon E_{M,a}^{SU} - \gamma D_a^{SU}, \\
\frac{dD_a^{QF}}{dt} &= d_a H M\varepsilon E_{M,a}^F - \gamma D_a^{QF}, \\
\frac{dD_a^{QS}}{dt} &= d_a H M\varepsilon E_{M,a}^{SU} + d_a \varepsilon E_a^Q - \gamma D_a^{QS}, \\
\frac{dU_a^F}{dt} &= (1-d_a)M\varepsilon E_{M,a}^F - \gamma U_a^F, \\
\frac{dU_a^S}{dt} &= (1-d_a)M\varepsilon (E_{M,a}^{SD} + E_{M,a}^{SU}) - \gamma U_a^S, \\
\frac{dU_a^Q}{dt} &= (1-d_a)M\varepsilon E_{M,a}^Q - \gamma U_a^Q,
\end{aligned}
$$

Here we have included M latent classes, giving rise to a Erlang distribution for the latent period, while the infectious period is exponentially distributed. The forces of infection which govern the non-linear transmission of infection obey:

$$\begin{aligned}
\lambda_a^F &= \sigma_a \sum_b \left(D_b^F + D_b^{SD} + D_b^{SU} + \tau(U_b^F + U_b^S)\right) \beta_{ba}^N, \\
\lambda_a^{SD} &= \sigma_a \sum_b D_b^F \beta_{ba}^H, \\
\lambda_a^{SU} &= \sigma_a \tau \sum_b U_a^F \beta_{ba}^H, \\
\lambda_a^Q &= \sigma_a \sum_b D_b^{QF} \beta_{ba}^H,
\end{aligned}$$

where β^H represents household transmission and $\beta^N = \beta^S + \beta^W + \beta^O$ represents all other transmission locations, comprising school-based transmission (β^S), work-place transmission (β^W) and transmission in all other locations (β^O). These matrices are taken from Prem et al [11], although other sources such as POLYMOD [12] could be used. σ_a corresponds to the age-dependent susceptibility of individuals to infection, d_a the age-dependent probability of displaying symptoms (and hence being detected), and τ represents reduced transmission of infection by undetectable individuals compared to detectable infections.

Amendments to within-household transmission

Our model explicitly assumes that all household transmission comes from the first case within the household. This would lead to a reduction in total onward transmission compared with a model where household saturation is ignored. Extensive simulations show that a simple multiplicative scaling to the household transmission ($\beta^H \to z\beta^H$, $z \approx 1.3$) generates a comparable match between the new model and one in which saturation effects are ignored, and we therefore include this scaling here.

Key Model Parameters

As with any model of this complexity, there are multiple parameters that determine the dynamics. Some of these are global parameters and apply for all geographical regions, with others used to capture the regional dynamics. Some of these parameters are fitted to the early outbreak and other data (table 1), however the majority are inferred by the MCMC process (table 2).

Relationship between age-dependent susceptibility and detectability

We interlink age-dependent susceptibility, σ_a, and detectability, d_a, by a quantity Q_a. Q_a can be viewed as the scaling between force of infection and symptomatic infection. Taking a next-generation approach, the early dynamics would be specified by:

$$R_0 D_a = d_a \sigma_a \beta_{ba}^N \left(D_a + \tau U_a\right)/\gamma \qquad R_0 U_a = (1 - d_a)\sigma_a \beta_{ba}^N \left(D_a + \tau U_a\right)/\gamma$$

where D_a measures those with detectable infections, which mirrors the early recorded age distribution of symptomatic cases. Explicitly, we let $d_a = \frac{1}{\kappa} Q_a^{(1-\alpha)}$ and $\sigma_a = \frac{1}{k} Q_a^{\alpha}$. As a consequence, $Q_a = \kappa k d_a \sigma_a$; where the parameters κ and k are determined such that the oldest age groups have a 90% probability of being symptomatic ($d_{>90} = 0.90$) and such that the basic reproductive ratio from these calculations gives $R_0 = 2.7$.

Table 1: Description of key model parameters not fitted in the MCMC and their source

Parameter	Description	Source
β	Age-dependent transmission, split into household, school, work and other	Matrices from Prem *et al.* [11]
γ	Recovery rate, changes with τ, the relative level of transmission from undetected asymptomatics compared to detected symptomatics	Fitted from early age-stratified UK case data to match growth rate and R_0
d_a	Age-dependent probability of displaying symptoms (and hence being detected), changes with α and τ	Fitted from early age-stratified UK case data to capture the age profile of infection.
σ_a	Age-dependent susceptibility, changes with α and τ	Fitted from early age-stratified UK case data to capture the age profile of infection.
H^R	Household quarantine proportion $= 0.8\phi_R$	Can be varied according to scenario
N_a^R	Population size of a given age within each region	ONS

Table 2: Description of key model parameters fitted in the MCMC

Parameter	Affects transmission?	Description
ε	Yes	Rate of progression to infectious disease ($1/\varepsilon$ is the duration in the exposed class). $\varepsilon \sim 0.2$
α	Yes	Scales the degree to which age-structured heterogeneity is due to age-dependent probability of symptoms ($\alpha = 0$) or age-dependent susceptibility ($\alpha = 1$)
τ	Yes	Relative level of transmission from asymptomatic compared to symptomatic infection
ϕ^R	Yes	Regional relative strength of the lockdown restrictions; scales the transmission matrices. Can also be varied according to scenario.
σ^R	Yes	Regional modifier of susceptibility to account for differences in level of social mixing
E_0^R	Yes	Regional initial regional level of infection, rescaled from early age-distribution of cases
Start date	Yes	Regional start date of the epidemic
S_T	No	Long term sensitivity of the serological test
D_S^R	No	Regional scaling for the mortality probability $P_a^{H\to Death}$
H_S^R	No	Regional scaling for the hospitalisation probability $P_a^{D\to H}$
I_S^R	No	Regional scaling for the ICU probability $P_a^{D\to I}$
H_s^R	No	Regional stretch factor for the hospitalisation time distribution $D_q^{D\to H}$
I_s^R	No	Regional stretch factor for the ICU admittance time distribution $D_q^{D\to I}$
Lag	No	Regional data reporting lag

Regional Heterogeneity in the Dynamics

Throughout the current epidemic, there has been noticeable heterogeneity between the different regions of England and between the devolved nations. In particular, London is observed to have a large proportion of early cases and a relatively steeper decline in the subsequent lock-down than the other regions and the devolved nations. In our model this heterogeneity is captured through three regional parameters which act on the heterogeneous population pyramid of each region.

Firstly, the initial level of infection in the region is re-scaled from the early age-distribution of cases, with the regional scaling factor set by the MCMC process. Secondly, we allow the age-dependent susceptibility to be scaled between regions (scaling factor I^R) to account for different levels of social mixing and hence differences in the early R_0 value. Finally, the relative strength of the lockdown (which may be time-varying) is again regional and is determined by the MCMC process.

3 Modelling social distancing

Age-structured contact matrices for the United Kingdom were obtained from Prem et al. [11] and used to provide information on household transmission (β^H_{ab}, with the subscript ab corresponding to transmission from age group a against age group b), school-based transmission (β^S_{ab}), work-place transmission (β^W_{ab}) and transmission in all other locations (β^O_{ab}). We assumed that the suite of social-distancing and lockdown measured acted in concert to reduce the work, school and other matrices while increasing the strength of household contacts.

We capture the impact of social-distancing by defining new transmission matrices ($B_{a,b}$) that represent the potential transmission in the presence of extreme lockdown. In particular, we assume that:

$$B^S_{ab} = q^S \beta^S_{ab}, \qquad B^W_{ab} = q^W \beta^W_{ab}, \qquad B^O_{ab} = q^O \beta^O_{ab},$$

while household mixing B^H is increased by up to a quarter to account for the greater time spent at home. We take $q^S = 0.05$, $q^W = 0.2$ and $q^O = 0.05$ to approximate the reduction in attendance at school, attendance at workplaces and engagement with shopping and leisure activities during the lock-down, respectively.

For a given compliance level, ϕ, we generate new transmission matrices as follows:

$$\begin{aligned}
\widehat{\beta}^H_{ab} &= (1-\phi)\beta^H_{ab} + \phi B^H_{ab} \\
\widehat{\beta}^S_{ab} &= (1-\phi)\beta^S_{ab} + \phi B^S_{ab} \\
\widehat{\beta}^W_{ab} &= (1-\theta)\left[(1-\phi)\beta^W_{ab} + \phi B^W_{ab}\right] + \theta\left((1-\phi) + \phi q^W\right)\left((1-\phi) + \phi q^O\right)\beta^W_{ab} \\
\widehat{\beta}^O_{ab} &= \beta^O_{ab}((1-\phi) + \phi q^O)^2
\end{aligned}$$

As such, home and school interactions are scaled between their pre-lockdown values (β) and post-lockdown limits (B) by the scaling parameter ϕ. Work interactions that are not in public-facing 'industries' (a proportion 1 - θ) were also assumed to scale in this manner; while those that interact with the general populations (such as shop-workers) were assumed to scale as both a function of their reduction and the reduction of others. We have assumed $\theta = 0.3$ throughout. Similarly, the reduction in transmission in other settings (generally shopping and leisure) has been assumed to scale with the reduction in activity of both members of any interaction, giving rise to a squared term.

4 Public Health Measurable Quantities

The main model equations focus on the epidemiological dynamics, allowing us to compute the number of symptomatic and asymptomatic infectious individuals over time. However, these quantities are not measured - and even the number of confirmed cases (the closest measure to symptomatic infections) is highly biased by the testing protocols at any given point in time. It is therefore necessary to convert infection estimates into quantities of interest that can be compared to data. We considered six such quantities which we calculated from the number of newly detectable symptomatic infections on a given day nD_d.

1. **Hospital Admissions:** We assume that a fraction $P_a^{D\to H}$ of detectable cases will be admitted into hospital after a delay q from the onset of symptoms. The delay, q, is drawn from a distribution $D_q^{D\to H}$ (note that $\sum_q D_q^{D\to H} = 1$.) Hospital admissions on day d of age a are therefore given by
$$H_a(d) = P_a^{D\to H} \sum_q D_q^{D\to H} nD_{d-q}$$

2. **ICU Admissions:** Similarly, a fraction $P_a^{D\to I}$ of detectable cases will be admitted into ICU after a delay, drawn from a distribution $D_q^{D\to I}$ which determines the time between the onset of symptoms and admission to ICU. ICU admissions on day d of age a are therefore given by
$$ICU_a(d) = P_a^{D\to I} \sum_q D_q^{D\to I} nD_{d-q}$$

3. **Hospital Beds Occupied:** Individuals admitted to hospital spend a variable number of days in hospital. We therefore define two weightings, which determine if someone admitted to hospital still occupies a hospital bed q days later (T_q^H) and if someone admitted to ICU occupies a hospital bed on a normal ward q days later ($T_q^{I\to H}$). Hospital beds occupied on day d of age a are therefore given by
$$H_a^o(d) = \sum_q H_a(d-q)T_q^H + \sum_q ICU_a(d-q)T_q^{I\to H}$$

4. **ICU Beds Occupied:** We similarly define T_q^I as the probability that someone admitted to ICU is still occupying a bed in ICU q days later. ICU beds occupied on day d of age a are therefore given by
$$ICU_a^o(d) = \sum_q ICU_a(d-q)T_q^I$$

5. **Number of Deaths:** The mortality ratio $P_a^{H\to Death}$ determines the probability that a hospitalised case of a given age, a, dies after a delay, q drawn from a distribution, $D_d^{H\to Death}$ between hospitalisation and death. The number of deaths on day d of age a are therefore given by
$$\text{Deaths}_a(d) = P_a^{H\to Death} \sum_q H_a(d-q)D_d^{H\to Death}$$

6. **Proportion testing seropositive:** Seropositivity is a function of time since the onset of symptoms; we therefore define an increasing sigmoidal function which determines the probability that someone who first displayed symptoms q days ago would generate a positive serology test from a blood sample. The shape of this sigmoidal function is matched to data from PHE, while the asymptote (the long-term sensitivity of the test, S_T) is a free parameter determined by the MCMC.

These nine distributions are all parameterised from individual patient data as recorded by the COVID-19 Hospitalisation in England Surveillance System (CHESS) [13] and the ISARIC WHO Clinical Characterisation Protocol UK (CCP-UK) database sourced from the COVID-19 Clinical Information Network (CO-CIN) [14, 15]. CHESS data is used to define the probabilities of different outcomes ($P_a^{D\to H}$, $P_a^{D\to I}$, $P_a^{H\to Death}$) due to its greater number of records, while CCP-UK is used to generate the distribution of times ($D_q^{D\to H}$, $D_q^{D\to I}$, $D_q^{H\to Death}$,T_q^H, T_q^I, $T_q^{D\to I}$) due to its greater detail.

However, these distributions all represent a national average and do not therefore reflect regional differences. We therefore define regional scalings of the three key probabilities ($P_a^{D\to H}$, $P_a^{D\to I}$ and $P_a^{H\to Death}$) and two additional parameters that can stretch (or contract) the distribution of times spent in hospital and ICU. These five regional parameters are necessary to get good agreement between key observations in all regions and may reflect both differences in risk groups (in addition to age) between regions or differences in how the data are recorded between devolved nations. We stress that these parameters do not influence the epidemiological dynamics.

5 Likelihood Function and the MCMC process

Multiple components form the likelihood function; most of which are based on a Poisson-likelihood. For brevity we define $L_P(n|x) = (n\ln(x) - x)\,/\log(n!)$ as the log of the probability of observing i given a Poisson distribution with mean x. Similarly $L_B(n|N,p)$ is the log of the binomial probability function. The log-likelihood function is then:

$$\begin{aligned}
LL^R(\theta) \;=\; & \sum_d L_P(\sum_a \text{Observed hospitalisations on day } d|\sum_a \text{Predicted hospitalisations on day } d) \\
& + \sum_d L_P(\sum_a \text{Observed ICU admissions on day } d|\sum_a \text{Predicted ICU admissions on day } d) \\
& + \sum_d L_P(\sum_a \text{Observed bed occupancy on day } d|\sum_a \text{Predicted bed occupancy on day } d) \\
& + \sum_d L_P(\sum_a \text{Observed ICU occupancy on day } d|\sum_a \text{Predicted ICU occupancy on day } d) \\
& + \sum_d L_P(\sum_a \text{Observed Deaths on day } d|\sum_a \text{Predicted Deaths on day } d) \\
& + \sum_d \sum_a L_B(\text{Observed positive serology tests on day } d|\text{Number of tests}, \text{Predicted} \\
& \qquad\qquad \text{proportion positive}).
\end{aligned}$$

This log-likelihood is the key component of the MCMC scheme. In the MCMC process, we apply multiple updates of the parameters using normal or log-normal proposal distributions about the current values. Some parameters (the scaling of age-structure α, the relative transmission rate τ, the latent period $1/\varepsilon$ and the test sensitivity S_T) are global and apply to all regions; new values of these are proposed and the log-likelihood calculated over all 10 regions. Other parameters are regional (such as the relative strength of lockdown restrictions ϕ^R) and can be updated for each region in turn, the ODEs simulated and stored. Finally another set of regional parameters govern how the ODE output is translated into public health measurable quantities (section 4). These can be rapidly applied to the solution to the ODEs and the likelihood calculated. Given the speed of this last set, multiple proposals are tested for each ODE replicate.

New data are available on a daily time-scale, and therefore inference needs to be repeated on a similar time-scale. We can take advantage of this sequential refitting, by using the posteriors of one inference

process as the initial conditions for the next, thus reducing the need for a long burn-in period.

6 Measuring the Growth Rate, r

The growth rate, r, is defined as the rate of exponential growth ($r > 0$) or decay ($r < 0$); and can be visualised as the gradient when plotting observables on a logarithmic scale. Figure 1 shows a simple example, whereby linear trends are fitted to the number of daily hospital admissions (per 100,000 people) in London. In this figure, three trend lines are plotted: one before lock-down; one during intense lock-down; and one after partial relaxation on 11th May. This plot clearly highlights the very different speeds between the initial rise and the long-term decline.

While such statistically simple approaches are intuitively appealing, there are three main drawbacks. Firstly, they are not easily able to cope with the distributed delay between a change in policy (such as the introduction of the lockdown) and the impact of observable quantities (with the delay to deaths being multiple weeks). Secondly, they cannot readily utilise multiple data streams. Finally, they can only be used to extrapolate into the future - extending the period of exponential behaviour - they cannot predict the impact of further changes to policy. Our approach is to instead fit the ODE model to multiple data streams, and then use the daily incidence to calculate the growth rate. Since we use a deterministic set of ODEs, the instantaneous growth rate r can be calculated on a daily basis.

There has been a strong emphasis (especially in the UK) on the value of the reproductive number (R) which measures the expected number of secondary cases from an infectious individual in an evolving outbreak. R brings together both the observed epidemic dynamics and the time-frame of the infection, and is thus subject to uncertainties in the latent and infectious periods as well as in their distribution - although the growth rate and the reproductive number have to agree at the point $r = 0$ and $R = 1$. We have two separate methods for calculating R which have been found to be in very close numerical agreement. The first is to calculate R from the next generation matrix β_{ba}/γ using the current distribution of infection across age-classes and states. The second (and numerically simpler method) is to use the relationship between R and r for an SEIR-type model with multiple latent classes, which gives

$$R = \left(1 + \frac{r}{\varepsilon M}\right)^M \left(1 + \frac{r}{\gamma}\right).$$

7 An Evolving Model Framework

Unsurprisingly, the model framework has evolved during the epidemic as more data streams have become available and as we have gained a better understanding of the epidemiology. Early models were largely based on the data from Wuhan, and made relatively crude assumptions about the times from symptoms to hospitalisation and death. Later models incorporated more regional variation, while the PHE serology data in early May had a profound impact on model parameters.

Figure 2 shows how our short-term predictions (each of 3-weeks duration) have changed over time, focusing on hospital admissions in London. It is clear that the early predictions were pessimistic about the reduction that would be generated by lockdown, although in part the higher values from early predictions is partly due to having identical parameters across all regions in the earliest models. In general later predictions, especially after the peak, are in far better agreement although the early inclusion of a step-change in the strength of the lockdown restrictions from 13th May (orange) led to substantial over-estimation of future hospital admissions. Across all regions we found some anomalous fits, which are due to changes in the way data were reported (figures 9 and 10).

The comparison of models and data over time can be made more formal by considering the mean



Fig. 1: Daily hospital admissions per 100,000 individuals in London. Points show the number of daily admissions to hospital (both in-patients testing positive and patients entering hospital following a positive test); results are plotted on a log scale. Three simple fits to the data are shown for pre-lockdown (red), strict-lockdown (blue) and relaxed-lockdown phases (green). Lines are linear fits to the logged data, returning average growth rates of 0.21 (doubling every 3.4 days), -0.06 (halving every 11.5 days) and -0.02 (halving every 34 days).



Fig. 2: Sequential comparison of model results and data. For all daily hospital admissions with COVID-19 in London, we show the raw data (block dots) and a set of short-term predictions generated at different points during the outbreak, changes to model fit reflect both improvements in model structure as well as increased amounts of data.



Fig. 3: Improvement in fit over time for the number of hospital deaths. Each dot represents a simulation date (colour-coded) and region. For a data stream x_t and model replicates y_t^i (where i accounts for sampling across the posterior parameter values) we compute the mean $\frac{1}{21}\sum_{T=t}^{t+20} x_T$; the prediction error $\frac{1}{21N}\sum_{i=1}^{N}\sum_{T=t}^{t+20}(x_T - y_T^i)^2$; the moving average $X_t = \frac{1}{6}(x_{t-3} + x_{t-2} + x_{t-1} + x_{t+1} + x_{t+2} + x_{t+3})$; and the moving average error $\frac{1}{21}\sum_{T=t}^{t+20}(x_T - X_T)^2$.

squared error across the 3-week prediction period for each region (figure 3). We compare three time varying quantities: (i) the mean value of the public health observable (in this case hospital deaths) in each region; (ii) the mean error between this data and the posterior set of ODE model predictions predicting forwards for 3 weeks; (iii) the mean error between the data and a simple moving average across the 3 time points before and after the data point. The top left hand graph shows a clear linear relationship between the mean value and the error from the moving average, giving support to our assumption (in the likelihood function) that the data is likely to be Poisson distributed such that the variance and mean are equal. The other two graphs show how the error in the prediction has dropped over time from very high values for simulations in early April (when the impact of the lockdown was uncertain) to values in late May and June that are comparable with the error from the moving average.

8 Choice of Parameters to Inform the Likelihood

The likelihood expression given above is an idealised measure, and depends on all the observed data streams being available and unbiased. Unfortunately, ICU admission data have not been available to date, and there are subtle differences in data streams between the devolved nations. An important question is therefore how key epidemiological quantities (and in particular the reproduction number R and the growth rate r) depend on the data sources used to underpin the dynamics.

Figure 4 (left panel) shows the impact of using different observables for London (other regions are shown in figure 11). Five different choices are shown: matching to recorded deaths only (using the date of death); matching to hospital admissions (both in-patients testing positive and admissions of individuals who have already tested positive); matching to bed occupancy, both hospital wards and ICU; matching to a combination of deaths and admissions; and finally matching to all data. In general we find that just using reported deaths produces the greatest spread of growth rates (r), presumably because deaths represent a small fraction of the total outbreak, and therefore naturally introduce more uncertainty. Using hospital admissions (with or without deaths) generates similar predictions and similar levels of uncertainty in predictions.



Fig. 4: Impact of data streams and model structure on estimated growth rate. Here the growth rates are estimated using the predicted rate of change of new cases for London on 10th June 2020, with parameters inferred using data until 9th June. **(a)** The impact of restricting the inference to different data streams (deaths only, hospital admissions, hospital bed occupancy, deaths and admissions or all data); serology data was included in all inference. **(b)** The impact of having different numbers of lockdown phases (while using all the data); the default is 3 (as in Figure 1).

As mentioned in section 7, the number of phases used to describe the reduction in transmission due to lockdown has changed as the situation, model and data evolved. The model began with just two phases; before and after lockdown. However, in late May, following the policy changes on 13th May, we explored having three phases. Having three phases is equivalent to assuming the same level of adherence to the lockdown and social-distancing measures throughout the epidemic, with changes in transmission occurring only due to the changing policy on 23rd March and 13th May. However, different number of phases can be explored (figure 4, right panel). Moving to four phases (with two equally spaced within the more relaxed lockdown) increases the variation, but does not have a substantial impact on the mean. Allowing eight phases (spaced every two weeks throughout lockdown) dramatically changes our estimation of the growth rate as the parameter inference responds more quickly to minor changes in observable quantities.

Lastly, it has been recently noted that one of the quantities used throughout the outbreak (number of daily hospital admissions) could be biasing the model fitting. Hospital admissions for COVID-19 are comprised of two measures:

(i) In-patients that test positive; this includes both individuals entering hospital with COVID-19 symptoms who subsequently test positive, and hospital acquired infections. Given that both of these elements feature in the hospital death data, it is difficult to separate them.

(ii) Patients arriving at hospital who have previously tested positive. In the early days of the outbreak, these were individuals who had been swabbed just prior to admission; however in the latter stages there are many patients being admitted for non-COVID related problems that have previously tested positive.

It seems prudent to remove this second element from our fitting procedure, although we note that for the devolved nations this separation into in-patients and new admissions is less clear. Removing this component of admissions also means that we cannot use the number of occupied beds as part of the likelihood, as these cannot be separated by the nature of admission. In figure 5 we therefore compare the default fitting (used throughout this paper) with an updated method that uses in-patient admissions (together with deaths, ICU occupancy and serology when available). We observe that restricting the definition of hospital admission leads to a slight reduction in the growth rate r but a more pronounced reduction in the incidence.

9 Current Fits and Results

Using the most recent fit to the data (as of the time of writing), which was performed on 14th June using in-patient data, ICU occupancy, date of death records and serological results, we analysed growth rate predictions and how growth rate predictions inferred at earlier times compare to current estimates. We focus on London and the North East and Yorkshire region, with other regions given in the Supplementary Material.

The time profile of predicted growth rate illustrates how the imposition of lockdown measures on 23rd March led to r decreasing below 0. The predicted growth rate is not a step function as changes to policy precipitate changes to the age-distribution of cases which has second-order effects on r. The second change in ϕ (the relative strength of lockdown restrictions) on 13th May, leads to an increase in r in all regions, although London shows one of the more pronounced increases. Despite this most recent increase, models estimates suggest r remained below 0 across all regions as of 14th June (figure 6).

Early changes in advice prior to the introduction of lockdown measures were also included in the model,



Fig. 5: Impact of including different types of hospital admission in parameter inference. Growth rates and total incidence (asymptomatic and symptomatic) estimated from the ODE model for June 10th 2020 in London. In each panel, blue dots (on the left-hand side) give estimates when using all hospital admissions in the parameter inference (together with deaths, ICU occupancy and serology when available); red dots (on the right-hand side) represent estimates obtained using an alternative inference method that restricted to fitting to in-patient hospital admission data (together with deaths, ICU occupancy and serology when available). Parameters were inferred using data until 9th June, while the r value comes from the predicted rate of change of new cases.



Fig. 6: Evolution of growth rate predictions and most recent model estimates. For two regions, **(left)** London, and **(right)** North East & Yorkshire, we show how predictions of r have evolved over time (dots and 95% credible intervals). These predictions are from the date the MCMC inference is performed. The solid blue line (together with 50% and 95% credible intervals) shows our estimate of r through time using the most recent fit to the data (performed on 14th June using in-patient data only). Vertical dashed lines show the two dates of main changes in policy, reflected in different regional ϕ values. Early changes in advice, such as social distancing, self isolation and working from home were also included in the model and their impact can be seen in minor declines in the estimated growth rate.

such as social distancing, encouragement to work from home (from 16th March) and the closure of all restaurants, pubs, cafes and schools on 20th March. For all regions, we observe minor declines in the estimated growth rate following introduction of these measures, though the estimated growth rate remained above 0 (figure 6).

As the model has evolved and the data streams become more complete, we have generally converged on the estimated growth rates from current inference. It is clear that it takes around 20 days from the time changes are enacted for them to be robustly incorporated into model parameters (see dots and 95% credible intervals in figure 6).

Using parameters drawn from the posterior distributions, the model produces predictive posterior distributions for multiple health outcome quantities that have a strong quantitative correspondence to the regional observations (figure 7). We recognise there was a looser resemblance to data on seropositivity, though salient features of the temporal profile are captured. In addition, short-term forecasts for each measure of interest have been made by continuing the simulation beyond the date of the final available data point, assuming that behaviour remains as of the final period (starting 13th May).



Fig. 7: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for London. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. In each panel: filled markers correspond to observed data, solid lines correspond to the mean outbreak over a sample of posterior parameters; shaded regions depict prediction intervals, with darker shading representing stricter confidence (dark shading - 50%, moderate shading - 90%, light shading - 99%). Predictions were produced using data up to 14th June.

Discussion

In this study, we have provided an overview of the evolving MCMC inference scheme employed for calibrating the Warwick COVID-19 model [10] to the available health care, mortality and serological data streams. A comparison of model short-term predictions and data over time (i.e. as the outbreak has progressed) demonstrated an observable decline in the error. Additionally, we have shown the variability that can arise in predictions of epidemiological metrics given user choices in fitted observables and how facets of the model framework may be parameterised. In particular, we have highlighted how differing methods of counting hospital admissions, though causing only slight differences in the estimated growth rate r, can lead to marked discrepancies in incidence.

It is important that uncertainty in the parameters governing the transmission dynamics, and its influence on predicted outcomes, be robustly conveyed. Without it, decision makers will be missing meaningful information and may assume a false sense of precision. MCMC methodologies were a suitable choice for inferring parameters in our model framework, since we were able to evaluate the likelihood function quickly enough to make the approach feasible. Nevertheless, for some model formulations and data, it may not be possible to write down or evaluate the likelihood function. In these circumstances, an alternative approach to parameter inference is via simulation-based, likelihood-free methods, such as Approximate Bayesian Computation [16–18].

As we enhance our collective understanding about the SARS-CoV-2 virus and the COVID-19 disease it causes, the structure of infectious disease transmission models, the inference procedure and the use of data streams to parameterise models must continuously evolve. One possible refinement to the model structure that may occur is a result of recent immunological assessments finding evidence of some infected individuals becoming seronegative within eight weeks of hospital discharge [19]. Thus, a waning seropositivity mechanism could warrant inclusion in the model, which may also strengthen correspondence to observed serology data in future fits. The knowledge that infection may be partially driven by nosocomial transmission [20, 21], while significant mortality is due to infection in care homes [22, 23], suggests that additional compartments capturing these components could greatly improve model realism if the necessary data was available throughout the course of the epidemic. Additionally, as we approach much lower levels of infection in the community, it may be prudent to adopt a stochastic model formulation at a finer spatial resolution to capture localised outbreak clusters.

A significant body of work exists describing the use of models during disease outbreaks and the parameterisation of these models to epidemiological data. In most cases, however, these models are fitted retrospectively, using the entire data that have been collected during an outbreak. In the case when models are deployed during active epidemics, there are additional challenges associated with the rapid flow of detailed and accurate data; even if robust models and methods were available from the start of an outbreak, there are still significant delays in obtaining, processing and inferring parameters from new information [5]. This is particularly crucial as new interventions are introduced or significant policy changes occur, such as the relaxation of multiple non-pharmaceutical interventions during May, June and July of 2020 or the introduction of the nationwide "test and trace" protocol [24].

In summary, if epidemiological models are to be used as part of the scientific discussion of controlling a disease outbreak it is vital that these models capture current biological understanding and are continually matched to all available data in real time. Our work on COVID-19 presented here highlights some of the challenges with predicting a novel outbreak in an rapidly changing environment. Probably the greatest weakness is the time that it inevitably takes to respond – both in terms of developing the appropriate model and inference structure, and the mechanisms to process any data sources, but also in terms of delay between real-world changes and their detection within any inference scheme. Both of these can be shortened by well-informed preparations, having the necessary suite of models

supported by the latest most efficient inference techniques could be hugely beneficial when rapid and robust predictive results are required.

Author contributions

Conceptualisation: Matt J. Keeling.

Data curation: Matt J. Keeling; Glen Guyver-Fletcher; Alexander Holmes.

CO-CIN Data provision: Malcolm G. Semple and the ISARIC4C Investigators.

Formal analysis: Matt J. Keeling.

Investigation: Matt J. Keeling.

Methodology: Matt J. Keeling.

Software: Matt J. Keeling; Edward M. Hill; Louise Dyson; Michael J. Tildesley.

Validation: Matt J. Keeling; Edward M. Hill; Louise Dyson; Michael J. Tildesley.

Visualisation: Matt J. Keeling.

Writing - original draft: Matt J. Keeling; Michael J. Tildesley; Edward M. Hill; Louise Dyson.

Writing - review & editing: Matt J. Keeling; Edward M. Hill; Glen Guyver-Fletcher; Alexander Holmes; Malcolm G. Semple; Louise Dyson; Michael J. Tildesley.

Patient and public involvement

This was an urgent public health research study in response to a Public Health Emergency of International Concern. Patients or the public were not involved in the design, conduct, or reporting of this rapid response research.

Financial disclosure

This work is supported by grants from: the National Institute for Health Research [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135]. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE. Study registration ISRCTN66726260.

This work has also been supported by the Engineering and Physical Sciences Research Council through the MathSys CDT [grant number EP/S022244/1] and by the Medical Research Council through the COVID-19 Rapid Response Rolling Call [grant number MR/V009761/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethical considerations

Ethical approval was given by the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013).

Data from the CHESS database were supplied after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Government's SPI-M(O) / SAGE committees.

Data availability

This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. We are extremely grateful to the 2,648 frontline NHS clinical and research staff and volunteer medical students, who collected this data in challenging circumstances; and the generosity of the participants and their families for their individual contributions in these difficult times. The CO-CIN data was collated by ISARIC4C Investigators. ISARIC4C welcomes applications for data and material access through our Independent Data and Material Access Committee (https://isaric4c.net).

Data on cases were obtained from the COVID-19 Hospitalisation in England Surveillance System (CHESS) data set that collects detailed data on patients infected with COVID-19. Data on COVID-19 deaths were obtained from Public Health England. These data contain confidential information, with public data deposition non-permissible for socioeconomic reasons. The CHESS data resides with the National Health Service (www.nhs.gov.uk) whilst the death data are available from Public Health England (www.phe.gov.uk).

Acknowledgements

We acknowledge the support of Jeremy J Farrar, Nahoko Shindo, Devika Dixit, Nipunie Rajapakse, Piero Olliaro, Lyndsey Castle, Martha Buckley, Debbie Malden, Katherine Newell, Kwame O'Neill, Emmanuelle Denis, Claire Petersen, Scott Mullaney, Sue MacFarlane, Chris Jones, Nicole Maziere, Katie Bullock, Emily Cass, William Reynolds, Milton Ashworth, Ben Catterall, Louise Cooper, Terry Foster, Paul Matthew Ridley, Anthony Evans, Catherine Hartley, Chris Dunn, Debby Sales, Diane Latawiec, Erwan Trochu, Eve Wilcock, Innocent Gerald Asiimwe, Isabel Garcia-Dorival, J. Eunice Zhang, Jack Pilgrim, Jane A Armstrong, Jordan J. Clark, Jordan Thomas, Katharine King, Katie Alexandra Ahmed, Krishanthi S Subramaniam , Lauren Lett, Laurence McEvoy, Libby van Tonder, Lucia Alicia Livoti, Nahida S Miah, Rebecca K. Shears, Rebecca Louise Jensen, Rebekah Penrice-Randal, Robyn Kiy, Samantha Leanne Barlow, Shadia Khandaker, Soeren Metelmann, Tessa Prince, Trevor R Jones, Benjamin Brennan, Agnieska Szemiel, Siddharth Bakshi, Daniella Lefteri, Maria Mancini, Julien Martinez, Angela Elliott, Joyce Mitchell, John McLauchlan, Aislynn Taggart, Oslem Dincarslan, Annette Lake, Claire Petersen, and Scott Mullaney.

Competing interests

MGS reports grants from DHSC NIHR UK, MRC UK, HPRU in Emerging and Zoonotic Infections, University of Liverpool during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, US outside the submitted work; the remaining authors declare no competing interests; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

ISARIC 4C Investigators

Consortium Lead Investigator: J Kenneth Baillie.
Chief Investigator: Malcolm G Semple.
Co-Lead Investigator: Peter JM Openshaw.
ISARIC Clinical Coordinator: Gail Carson.

Co-Investigators: Beatrice Alex, Benjamin Bach, Wendy S Barclay, Debby Bogaert, Meera Chand, Graham S Cooke, Annemarie B Docherty, Jake Dunning, Ana da Silva Filipe, Tom Fletcher, Christopher A Green, Ewen M Harrison, Julian A Hiscox, Antonia Ying Wai Ho, Peter W Horby, Samreen Ijaz, Saye Khoo, Paul Klenerman, Andrew Law, Wei Shen Lim, Alexander, J Mentzer, Laura Merson, Alison M Meynert, Mahdad Noursadeghi, Shona C Moore, Massimo Palmarini, William A Paxton, Georgios Pollakis, Nicholas Price, Andrew Rambaut, David L Robertson, Clark D Russell, Vanessa Sancho-Shimizu, Janet T Scott, Louise Sigfrid, Tom Solomon, Shiranee Sriskandan, David Stuart, Charlotte Summers, Richard S Tedder, Emma C Thomson, Ryan S Thwaites, Lance CW Turtle, Maria Zambon. Project Managers Hayley Hardwick, Chloe Donohue, Jane Ewins, Wilna Oosthuyzen, Fiona Griffiths. Data Analysts: Lisa Norman, Riinu Pius, Tom M Drake, Cameron J Fairfield, Stephen Knight, Kenneth A Mclean, Derek Murphy, Catherine A Shaw. Data and Information System Manager: Jo Dalton, Michelle Girvan, Egle Saviciute, Stephanie Roberts Janet Harrison, Laura Marsh, Marie Connor. Data integration and presentation: Gary Leeming, Andrew Law, Ross Hendry. Material Management: William Greenhalf, Victoria Shaw, Sarah McDonald. Outbreak Laboratory Volunteers: Katie A. Ahmed, Jane A Armstrong, Milton Ashworth, Innocent G Asiimwe, Siddharth Bakshi, Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Benjamin WA Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lewis WS Fisher, Terry Foster, Isabel Garcia-Dorival, Willliam Greenhalf, Philip Gunning, Catherine Hartley, Antonia Ho, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khandaker, Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane Latawiec, L Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria Mancini, Sarah McDonald, Laurence McEvoy, John McLauchlan, Soeren Metelmann, Nahida S Miah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Subramaniam, Agnieska Szemiel, Aislynn Taggart, Jolanta Tanianis, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve Wilcock, J. Eunice Zhang. Local Principal Investigators: Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, Ana Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge , Nicola Best , Pieter Bothma, David Brealey, Robin Brittain-Long, Naomi Bulteel, Tom Burden , Andrew Burtenshaw, Vikki Caruth, David Chadwick, Duncan Chambler, Nigel Chee, Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite, Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans , Chi Eziefula, Chrisopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, Atul Garg, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke Hodgson, Anita Holme, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy , Shondipon Laha, Susan Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, Huw Masson , Elijah Matovu, Katherine McCullough, Ruth McEwen , Manjula Meda, Gary Mills , Jane Minton, Mariyam Mirfenderesky, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore,

Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Megan Nagel, Thapas Nagarajan, Mark Nelson, Igor Otahal, Mark Pais, Selva Panchatsharam, Hassan Paraiso, Brij Patel, Justin Pepperell, Mark Peters, Mandeep Phull , Stefania Pintus, Jagtur Singh Pooni, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alistair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Aarti Shah, Prad Shanmuga, Anil Sharma, Anna Shawcross, Jeremy Sizer, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines , Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio Tridente, Darell Tupper - Carey, Mary Twagira, Andrew Ustianowski, Nick Vallotton, Lisa Vincent-Smith, Shico Visuvanathan , Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme Wijesinghe, Martin Williams, Lawrence Wilson, Sarah Wilson, Stephen Winchester, Martin Wiselka, Adam Wolverson, Daniel G Wooton, Andrew Workman, Bryan Yates, Peter Young.

SUPPLEMENTARY MATERIAL



Fig. 8: Linear fits to daily hospital admissions per 100,000 individuals in each region. Points show the number of daily admissions to hospital (both in-patients testing positive and patients entering hospital following a positive test); results are plotted on a log scale. Three simple fits to the data are shown for pre-lockdown (red), strict-lockdown (blue) and relaxed-lockdown phases (green). Fits are a limit linear fit to the logged data (mean estimates depicted by solid lines, 95% confidence intervals by the dashed lines).



Fig. 9: Sequential comparison of daily hospital admission model results and data in each region. For all daily hospital admissions with COVID-19 in each region, we show the raw data (block dots) and a set of short-term predictions generated at different points during the outbreak. Changes to model fit reflect both improvements in model structure as well as increased amounts of data.



Fig. 10: Sequential comparison of daily hospital death model results and data in each region. For all daily hospital deaths with COVID-19 in each region, we show the raw data (block dots) and a set of short-term predictions generated at different points during the outbreak. Changes to model fit reflect both improvements in model structure as well as increased amounts of data.



Fig. 11: Impact of data streams on estimated growth rates, by region. The impact on the regional growth rate (estimated from the ODE epidemic on 10th June 2020) of restricting the inference to different data streams (deaths only, hospital admissions, hospital bed occupancy, deaths and admissions or all data); the serology data was included in all inference. Parameters were inferred using data until 9th June, while the r value comes from the change in predicted rate of change of new cases.



Fig. 12: Impact of model structure on estimated growth rates, by region. Analysis of having different numbers of lockdown phases on the estimated regional growth rate on 10th June 2020, while using all the data. The number of lockdown phases tested were there (blue dots), four (green dots) and eight (red dots). Parameters were inferred using data until 9th June, while the r value comes from the change in predicted rate of change of new cases.



Fig. 13: Impact of including different types of hospital admission in parameter inference on the estimated regional growth rates (on 10th June 2020). For each region, growth rates were estimated from the ODE epidemic for 10th June 2020. In each panel, blue dots (on the left-hand side) give r estimates when using all hospital admissions in the parameter inference (together with deaths, ICU occupancy and serology when available); red dots (on the right-hand side) represent r estimates using an alternative inference method that restricted to fitting to in-patient hospital admission data (together with deaths, ICU occupancy and serology when available). Parameters were inferred using data until 9th June, while the r value comes from the change in predicted rate of change of new cases. We observe that restricting the definition of hospital admission leads to a slight reduction in the growth rate r but a more pronounced reduction in the incidence. (This separation is not possible for the devolved nations, but the associated distributions are shown for completeness.)



Fig. 14: Impact of including different types of hospital admission in parameter inference on the daily incidence (on 10th June 2020). For each region, daily incidences were estimated from the ODE epidemic for 10th June 2020. In each panel, blue dots (on the left-hand side) give incidence estimates when using all hospital admissions in the parameter inference (together with deaths, ICU occupancy and serology when available); red dots (on the right-hand side) represent incidence estimates using an alternative inference method that restricted to fitting to in-patient hospital admission data (together with deaths, ICU occupancy and serology when available). Parameters were inferred using data until 9th June. We observe that restricting the definition of hospital admission leads to a pronounced reduction in the incidence. (This separation is not possible for the devolved nations, but the associated distributions are shown for completeness.)



Fig. 15: Evolution of growth rate predictions and most recent model estimates in each of the ten regions. For each region, we show how predictions of r have evolved over time (dots and 95% credible intervals). These predictions are from the date the MCMC inference is performed. The solid blue line (together with 50% and 95% credible intervals) shows our estimate of r through time using the most recent fit to the data (performed on 14th June using in-patient data only). Vertical dashed lines show the two dates of main changes in policy, reflected in different regional ϕ values.



Fig. 16: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the East of England region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 17: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the Midlands region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 18: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the North East & Yorkshire region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 19: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the North West region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 20: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the South East region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 21: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for the South West region. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 22: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for Wales. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 23: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for Scotland. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.



Fig. 24: Health outcome predictions of the ODE from the beginning of the outbreak and 3 weeks into the future for Northern Ireland. (Top left) Daily deaths; **(top right)** seropositivity percentage; **(bottom left)** daily hospital admissions; **(bottom right)** ICU occupancy. Predictions were produced using data up to 14th June.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* **382**(8):727–733 (2020). doi:10.1056/NEJMoa2001017.

[2] World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report - 1. (2020). URL https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4. [Online] (Accessed: 29 July 2020).

[3] World Health Organization. Coronavirus diseases (COVID-19) Situation Report - 196. (2020). URL https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200803-covid-19-sitrep-196-cleared.pdf?sfvrsn=8a8a3ca4_4. [Online] (Accessed: 04 August 2020).

[4] UK Government. Scientific Pandemic Influenza Group on Modelling (SPI-M) (2020). URL https://www.gov.uk/government/groups/scientific-pandemic-influenza-subgroup-on-modelling. [Online] (Accessed: 29 July 2020).

[5] De Angelis D, Presanis AM, Birrell PJ, Tomba GS, House T. Four key challenges in infectious disease modelling using data from multiple sources. *Epidemics* **10**:83–87 (2015). doi:https://doi.org/10.1016/j.epidem.2014.09.004.

[6] Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, *et al.* *Bayesian Data Analysis*. Chapman and Hall/CRC (2013). doi:10.1201/b16018.

[7] Brooks S, Gelman A, Jones G, Meng XL, editors. *Handbook of Markov Chain Monte Carlo*. Chapman and Hall/CRC (2011). doi:10.1201/b10905.

[8] Thompson RN. Epidemiological models are important tools for guiding COVID-19 interventions. *BMC Med.* **18**(1):152 (2020). doi:10.1186/s12916-020-01628-4.

[9] Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, *et al.* Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. *Lancet Public Heal.* (2020). doi:10.1016/S2468-2667(20)30133-X.

[10] Keeling MJ, Hill E, Gorsich E, Penman B, Guyver-Fletcher G, *et al.* Predictions of COVID-19 dynamics in the UK: short-term forecasting and analysis of potential exit strategies. *medRxiv* page 2020.05.10.20083683 (2020). doi:10.1101/2020.05.10.20083683.

[11] Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. *PLOS Comput. Biol.* **13**(9):e1005697 (2017). doi:10.1371/journal.pcbi.1005697.

[12] Mossong J, Hens N, Jit M, Beutels P, Auranen K, *et al.* Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. *PLoS Med.* **5**(3):e74 (2008). doi:10.1371/journal.pmed.0050074.

[13] Public Health England. COVID-19 Hospitalisation in England Surveillance System (CHESS) – daily reporting. (2020). URL https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/phe-letter-to-trusts-re-daily-covid-19-hospital-surveillance-11-march-2020.pdf. [Online] (Accessed: 29 July 2020).

[14] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, *et al.* Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* **369**:m1985 (2020). doi:10.1136/bmj.m1985.

[15] ISARIC 4C (Coronavirus Clinical Characterisation Consortium) (2020). URL https://isaric4c.net. [Online] (Accessed: 29 July 2020).

[16] Beaumont MA, Cornuet JM, Marin JM, Robert CP. Adaptive approximate Bayesian computation. *Biometrika* **96**(4):983–990 (2009). doi:10.1093/biomet/asp052.

[17] Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP. Approximate Bayesian computation scheme for parameter inference and model selection in dynamical systems. *J. R. Soc. Interface* **6**(31):187–202 (2009). doi:10.1098/rsif.2008.0172.

[18] McKinley T, Cook AR, Deardon R. Inference in Epidemic Models without Likelihoods. *Int. J.*

Biostat. **5**(1) (2009). doi:10.2202/1557-4679.1171.

[19] Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat. Med.* (2020). doi:10.1038/s41591-020-0965-6.

[20] Zhou Q, Gao Y, Wang X, Liu R, Du P, *et al.* Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. *Ann. Transl. Med.* **8**(10):629 (2020). doi:10.21037/atm-20-3324.

[21] Evans S, Agnew E, Vynnycky E, Robotham JV. The impact of testing and infection prevention and control strategies on within-hospital transmission dynamics of COVID-19 in English hospitals. *medRxiv* page 2020.05.12.20095562 (2020). doi:10.1101/2020.05.12.20095562.

[22] O'Dowd A. Covid-19: Care home deaths in England and Wales rise sharply. *BMJ* **369**:m1727 (2020).

[23] Graham NS, Junghans C, Downes R, Sendall C, Lai H, *et al.* Sars-cov-2 infection, clinical features and outcome of covid-19 in united kingdom nursing homes. *Journal of Infection* (2020).

[24] Department of Health and Social Care. NHS test and trace: how it works. (2020). URL https://www.gov.uk/guidance/nhs-test-and-trace-how-it-works. [Online] (Accessed: 29 July 2020).